ABSTRACT Hydroxyurea as an indirect antithrombotic agent: In Myeloproliferative neoplasms (MPNs) thrombosis is an important cause of morbidity and mortality and some experimental studies reported an indirect, but significant, anti-thrombotic efficacy of hydroxyurea (HU), currently the most used cytoreductive agent in these disorders (1-2). HU was studied in important randomized clinical trials, one carried out in Polycitemia Vera (PV) and two in Esssential Thrombocytemia (ET) patients (3). In summary Finazzi describes these last studies, one trial comparing HU with a randomized untreated control group performed in 114 patients with ET and a high risk of thrombosis, and another comparing HU plus low-dose aspirin with anagrelide plus low-dose aspirin in 809 ET high-risk. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. Hydroxyurea mediated release of nitric oxide in myeloproliferative neoplasms patients: Effects on platelet-leukocyte interaction - ResearchGate. Available from: http://www.researchgate.net/publication/277081198_Hydroxyurea_mediated_release_of_nitric_oxide_in_myeloproliferative_neoplasms_patients_Effects_on_platelet-leukocyte_interaction [accessed Oct 12, 2015].
- myeloproliferative neoplasms